Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01622283
Other study ID # 116459
Secondary ID
Status Completed
Phase Phase 1
First received April 19, 2012
Last updated June 9, 2017
Start date May 2, 2012
Est. completion date June 10, 2012

Study information

Verified date June 2017
Source GlaxoSmithKline
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study will be a single center, open-label, randomized, single dose, in the fasted condition and 2-way crossover study to evaluate the pharmacokinetics, the safety and tolerability of levocetirizine oral solution 5 mg and cetirizine dry syrup 10 mg in Japanese healthy male subjects.

Approximately 20 subjects will receive both treatments of levocetirizine oral solution 5 mg and cetirizine dry syrup 10 mg in the design. Serial pharmacokinetic samples will be collected and safety assessments will be performed following each dose.

The primary objective of the study is to demonstrate the bioequivalence of levocetirizine in plasma, when given as levocetirizine oral solution 5 mg relative to cetirizine DS 10 mg in Japanese healthy male subjects.


Recruitment information / eligibility

Status Completed
Enrollment 20
Est. completion date June 10, 2012
Est. primary completion date June 10, 2012
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Male
Age group 20 Years to 55 Years
Eligibility Inclusion Criteria:

- Healthy as determined by a responsible and experienced physician, based on a medical evaluation including medical history, physical examination, laboratory tests and cardiac monitoring. A subject with a clinical abnormality or laboratory parameters outside the reference range for the population being studied may be included only if the Investigator and the GSK Medical Monitor agree that the finding is unlikely to introduce additional risk factors and will not interfere with the study procedures.

- Japanese male between 20 and 55 years of age inclusive, at the time of signing the informed consent.

- Non-smoker or ex-smoker having ceased smoking for at least 6 months.

- Body weight => 50 kg and BMI within the range 18.5 - 25.0 kg/m2 at screening.

- A signed and dated written informed consent is obtained from the subject.

- Able to complete all study procedures and planned treatment periods.

- ALT, alkaline phosphatase and bilirubin =< 1.5xULN (isolated bilirubin > 1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin < 35%).

- Single QTcB < 450 msec at screening.

Exclusion Criteria:

- The subject is positive for syphilis, Hepatitis B surface antigen, Hepatitis C antibody, HIV1/2 antibody, or HTLV-1 antibody at screening.

- Current or chronic history of liver disease, or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones).

- The subject has a history of allergic rhinitis.

- The subject is currently participating in another clinical study or post-marketing study in which the subject is or will be exposed to an investigational or a non-investigational drug or device.

- The subject has a history or current conditions of drug abuse or alcoholism.

- A positive pre-study drug screen.

- History of regular alcohol consumption within 6 months of the study defined as an average weekly intake of >14 drinks. One drink is equivalent to 12 g of alcohol: 12 ounces (350 mL) of beer, 5 ounces (150 mL) of wine or 1.5 ounces (45 mL) of 80 proof distilled spirits.

- The subject has participated in a clinical trial and has received an investigational product or a non-investigational drug within 4 months prior to the first dosing day in the current study.

- Exposure to more than four new chemical entities within 12 months prior to the first dosing day.

- Unable to refrain from the use of prescription or non-prescription drugs, including vitamins, herbal and dietary supplements (including St John's Wort) within 14 days or 5 half-lives (whichever is longer) prior to the first dose of study medication, unless in the opinion of the Investigator and GSK Medical Monitor the medication will not interfere with the study procedures or compromise subject safety.

- History of sensitivity to any of the study medications, or components thereof or a history of drug or other allergy.

- Where participation in the study would result in donation of blood or blood products => 400 mL within 3 months or => 200 mL within 1 month.

- Unwillingness or inability to follow the procedures outlined in the protocol.

- Subject is mentally or legally incapacitated.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Levocetirizine
Levocetirizine
Cetirizine
Cetirizine

Locations

Country Name City State
Japan GSK Investigational Site Kagoshima

Sponsors (1)

Lead Sponsor Collaborator
GlaxoSmithKline

Country where clinical trial is conducted

Japan, 

Outcome

Type Measure Description Time frame Safety issue
Primary AUC(0-48) of levocetirizine AUC(0-48): Area under plasma concentration time curve from pre-dose to 48h. pre, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 9, 12, 16, 24, 36, 48h post dose
Primary Cmax of levocetirizine Cmax: Maximum observed concentration. pre, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 9, 12, 16, 24, 36, 48h post dose
Secondary Adverse events Number of participants with adverse events as a measure of safety and tolerability. up to 48h post dose
Secondary Safety and tolerability Safety and tolerability of levocetirizine and cetirizine in terms of clinical laboratory tests, vital sign, body weight and ECG. up to 48h post dose
Secondary Vital sign Systolic and diastolic blood pressure, body temperature and pulse rate. up to 48h post dose
Secondary Body weight up to 48h post dose
Secondary ECG Heart rate, PR, QRS, QT, and QTc intervals. up to 48h post dose
Secondary Laboratory tests Clinical Chemistry (Total Protein, Albumin, Total and Direct Bilirubin, BUN, Creatinine, Uric Acid, TG, Total Cholesterol, LDL and HDL-cholesterol, AST, ALT, Alkaline Phosphatase, LDH, GGT, CPK, Amylase, Glucose(fasting), Sodium, Potassium, Chloride, Calcium, Phosphorus), Hematology (Platelet Count, RBC Count, WBC Count (absolute), Reticulocyte Count, Hemoglobin, Hematocrit, RBC Indices (MCV, MCH, MCHC) and Automated WBC Differential (Neutrophils, Lymphocytes, Monocytes, Eosinophils, Basophils)) and Urinalysis (Specific Gravity, pH, Glucose, Protein, Blood, Ketones and Microscopic Examination) up to 48h post dose
Secondary AUC(0-inf), MRT, tmax, and t1/2 of levocetirizine AUC(0-inf): Area under the concentration-time curve from time pre-dose extrapolated to infinite time, MRT: Mean residence time, tmax: Time of occurrence of Cmax, and t1/2: Terminal phase half-life. pre, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 9, 12, 16, 24, 36, 48h post dose
See also
  Status Clinical Trial Phase
Completed NCT02424539 - A Study to Compare the Efficacy and Safety of Fluticasone Furoate Nasal Sprays (FFNS) 55 Microgram (mcg) and 110 mcg in Chinese Pediatric Subjects With Allergic Rhinitis (AR) Phase 4
Completed NCT01957202 - A Proof of Concept Study to Assess Effect of Fluticasone Furoate (FF)/Levocabastine Fixed Dose Combination (FDC) Compared With Levocabastine and FF Alone in Subjects With Allergic Rhinitis (AR) Phase 2
Completed NCT01949051 - A Study to Assess Intranasal Repeat Dose Effect of Levocabastine in the Subjects With Allergic Rhinitis Phase 2
Completed NCT01962467 - A Relative Bioavailability Study of Fluticasone Furoate and Levocabastine Phase 1
Completed NCT01001130 - Regulatory AVAMYS Nasal Spray PMS N/A
Completed NCT02397915 - Patient Preference Study of Fluticasone Furoate and Mometasone Furoate Nasal Sprays Phase 4
Completed NCT01445262 - Drug Use Investigation for XYZAL® N/A
Completed NCT01916226 - A Comparator Study of Fluticasone Propionate Nasal Spray Verses (vs) Cetirizine in the Treatment of Seasonal Allergic Rhinitis Phase 4
Completed NCT00109486 - Safety Study To Assess Growth In Children With Seasonal Allergic And/Or Perennial Allergic Rhinitis Treated With GW685698X Aqueous Nasal Spray Or Placebo Nasal Spray Phase 3